India produces nearly 20% of global generic drugs. PLI-incentivised API capacity is reaching full production
in 2026. The export diversification story is just beginning.
India’s pharmaceutical API market is valued at $14.18 billion in 2025 and is projected to reach $22.18 billion by
2031 at a 7.74% CAGR. India produces nearly 20% of all generic drugs used globally, supplies approximately 40% of US generic medicine demand, and meets around 25% of UK generic medicines requirements. It hosts over 600 FDA-approved facilities and more than 1,400 WHO-GMP certified manufacturing sites – the most complete regulatory credential base of any API sourcing geography in the world.
The export diversification story is the forward angle. Indian pharma exports in early FY2026 reached approximately $4.96 billion, with finished formulations making up three-quarters of total shipments. The US accounts for 34–35% of exports. Africa and Latin America are growing – Nigeria and Kenya have joined the top 15 export destinations. The strategic risk being actively managed is geographic concentration: the same logic that drove China+1 sourcing in chemicals and electronics is now driving API supply chain diversification, and India is the principal beneficiary.
The structural shift in 2026 is that PLI-incentivised domestic API manufacturing capacity is now reaching full
operational status. New capacity across bulk drug parks and integrated API manufacturing facilities is translating into export readiness across a broader range of molecules – from cardiovascular and oncology APIs to high-potency compounds and biological APIs, which are growing at 9.22% CAGR through 2031. Cipla signed a multi-year API supply agreement with a leading European pharmaceutical company in early 2025. Biocon is expanding into GLP-1 and generic obesity treatment APIs, where global demand is surging.
For destination markets, the opportunity runs in two directions. The first is as a recipient of Indian pharma
investment – commercial offices, regulatory affairs hubs, and regional distribution infrastructure are following the export relationships. The second is as a supply chain partner for markets that want to build local pharmaceutical manufacturing capacity with Indian technical and operational support.
India’s pharmaceutical sector has been a global supply chain anchor for two decades. The API diversification and export expansion of 2026 are extending that position into new geographies and new therapeutic categories.
Nueconomy tracks outbound signals from India’s pharmaceutical and API sector through CUE.
If you are a destination market positioning for Indian pharma investment or supply chain partnership positioning for Indian pharmaceutical API export diversification and investment, we can help identify the right
companies and the right conversation.
hello@nueconomy.co · thenueconomy.com
Related: PLI Built the Base
